2023 Guidance and Q3 Earnings

67 potential new vaccines and medicines in pipeline Phase III/Registration – 17 assets Arexvy (RSV vaccine) gepotidacin (2140944) bepirovirsen (3228836) Bexsero (MenB vaccine) MenABCWY vaccine (3536819) tebipenem pivoxil (3778712) ibrexafungerp (5458448) Nucala (mepolizumab) depemokimab (3511294) latozinemab (4527223) camlipixant (5464714) Ojjaara (momelotinib) Recombinant protein, adjuvanted* BTI inhibitor* Antisense oligonucleotide* Recombinant protein, OMV Recombinant protein, OMV, conjugated vaccine Antibacterial carbapenem* Antifungal glucan synthase inhibitor* Anti-IL5 antibody Long-acting anti-IL5 antibody* Anti-sortilin antibody* P2X3 receptor antagonist JAK1, JAK2 and ACVR1 inhibitor* Anti-PD-1 antibody* PARP inhibitor* Blenrep (belantamab mafodotin) Anti-BCMA ADC* Jemperli (dostarlimab) Zejula (niraparib) cobolimab (4069889) linerixibat (2330672) Anti-TIM-3 antibody* IBAT inhibitor RSV older adults (50-59 YoA) Uncomplicated UTI** Hepatitis B virus** Meningitis B (infants US) MenABCWY, 1st Gen Complicated UTI? Invasive candidiasis COPD Asthma** Frontotemporal dementia 8** Refractory chronic cough Myelofibrosis^⁹ Endometrial cancer^** Ovarian cancer** Multiple myeloma Non-small cell lung cancer Cholestatic pruritus in primary biliary cholangitis Infectious diseases HIV (ViiV) Respiratory/Immunology Oncology Opportunity driven GSK *In-licence or other alliance relationship with third party **Additional indications or candidates also under investigation In registration 1. In phase I/II study 2. Transition activities underway to enable further progression by partner 3. Phase I study start imminent 4. GSK has an exclusive global license option to co-develop and commercialise the candidate 5. GSK has exclusive option to co-develop post phase II 6. Phase II study start imminent 7. Phase III study start expected in 2023 8. Phase III trial in patients with progranulin gene mutation 9. Approved in US 36

View entire presentation